CGEM Stock Price, Cullinan Management, . Quote, Chart

Market Summary

USD23.16-0.65

Delayed

-2.73%

CGEM Alerts

1 major insider sales recently.

Big jump in Earnings (Y/Y)
Losses in recent quarter

CGEM Stock Price

View Fullscreen

CGEM RSI Chart

CGEM Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-10.09

Price/Sales (Trailing)

14.35

EV/EBITDA

-7.46

Price/Free Cashflow

-10.98

CGEM Price/Sales (Trailing)

CGEM Profitability

EBT Margin

-157.52%

Return on Equity

-31.07%

Return on Assets

-29.43%

Free Cashflow Yield

-9.11%

CGEM Fundamentals

CGEM Revenue

Revenue (TTM)

107.4M

CGEM Earnings

Earnings (TTM)

-132.3M

Earnings Growth (Yr)

36.11%

Earnings Growth (Qtr)

-56.65%

Breaking Down CGEM Revenue

Last 7 days

-12.8%

Last 30 days

29.5%

Last 90 days

27.0%

Trailing 12 Months

163.2%

How does CGEM drawdown profile look like?

CGEM Financial Health

Current Ratio

20.33

CGEM Investor Care

Shares Dilution (1Y)

46.43%

Diluted EPS (TTM)

-3.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2024	0	0	0
2023	0	0	0
2022	173.6M	140.5M	107.4M
2021	0	0	18.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cullinan Management, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	michaelson jennifer	sold	-168,516	30.06	-5,606	chief scientific officer
May 07, 2024	michaelson jennifer	acquired	24,105	4.3	5,606	chief scientific officer
May 06, 2024	michaelson jennifer	sold	-1,628,160	28.0717	-58,000	chief scientific officer
May 06, 2024	michaelson jennifer	acquired	215,000	4.3	50,000	chief scientific officer
Feb 22, 2024	jones jeffrey alan	acquired	-	-	62,500	chief medical officer
Feb 22, 2024	savill corrine	acquired	-	-	37,500	chief business officer
Feb 22, 2024	michaelson jennifer	acquired	-	-	50,000	chief scientific officer
Feb 22, 2024	sumer jacquelyn l	acquired	-	-	50,000	chief legal officer
Feb 22, 2024	ahmed nadim	acquired	-	-	160,000	president and ceo
Feb 22, 2024	trigilio jeffrey	acquired	-	-	50,000	chief financial officer

Which funds bought or sold CGEM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	835	2,078	-%
May 16, 2024	JANE STREET GROUP, LLC	added	52.18	217,265	357,908	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.75	147,936	404,734	-%
May 15, 2024	AMERIPRISE FINANCIAL INC	added	665	6,600,850	7,160,500	-%
May 15, 2024	Blue Owl Capital Holdings LP	reduced	-14.47	14,991,100	49,839,300	9.96%
May 15, 2024	Point72 (DIFC) Ltd	new	-	21,688	21,688	-%
May 15, 2024	Paradigm Biocapital Advisors LP	new	-	22,970,200	22,970,200	0.81%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	new	-	1,164,820	1,164,820	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	3.72	165,000	390,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-3.00	858,339	2,238,190	-%

Are Funds Buying or Selling CGEM?

Are funds buying CGEM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CGEM

No. of Funds

Unveiling Cullinan Management, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 24, 2024	flynn james e	5.71%	3,283,824	SC 13G
Feb 14, 2024	blue owl capital holdings lp	7.99%	3,419,842	SC 13G
Feb 14, 2024	biotechnology value fund l p	6.5%	2,870,427	SC 13G/A
Feb 14, 2024	jovan-embiricos morana	1.10%	468,696	SC 13G/A
Feb 13, 2024	vanguard group inc	4.14%	1,771,443	SC 13G/A
Feb 06, 2024	franklin resources inc	7.7%	3,281,280	SC 13G
Jan 29, 2024	blackrock inc.	5.8%	2,462,274	SC 13G
Sep 07, 2023	blackrock inc.	4.8%	2,036,651	SC 13G/A
Feb 15, 2023	jovan-embiricos morana	3.4%	1,577,440	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	8.9%	4,058,854	SC 13G/A

Recent SEC filings of Cullinan Management, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	3	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	ARS	ARS
May 16, 2024	DEF 14A	DEF 14A
May 16, 2024	DEFA14A	DEFA14A
May 16, 2024	S-3	S-3
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 08, 2024	4	Insider Trading
May 06, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Cullinan Management, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cullinan Management, Inc. News

Latest updates

Cullinan Management, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-	-	-	-	-	174	-	-	-	19.00
Operating Expenses	-31.5%	43.00	63.00	33.00	30.00	37.00	34.00	18.00	17.00	18.00
S&GA Expenses	-100.0%	-	11.00	11.00	10.00	11.00	13.00	6.00	5.00	5.00
R&D Expenses	-41.2%	31.00	52.00	21.00	20.00	26.00	21.00	13.00	12.00	12.00
EBITDA Margin	-234.2%	-1.57*	1.17*	1.41*	1.04*	0.89*	-3.56*	-	-	-
Income Taxes	-	-	-	-1.88	-2.50	66.00	-	-	-	-
Earnings Before Taxes	100.0%	-	-58.14	-28.95	-27.41	240	-34.21	-18.26	-16.44	1.00
EBT Margin	-234.7%	-1.58*	1.17*	1.41*	1.04*	0.89*	-3.56*	-	-	-
Net Income	36.1%	-37.15	-58.14	-	-24.80	174	-32.86	-17.35	-16.44	1.00
Net Income Margin	-218.9%	-1.23*	1.04*	1.04*	0.74*	0.64*	-3.44*	-	-	-
Free Cashflow	25.2%	-38.25	-51.16	-25.86	-54.60	-25.42	-15.17	-10.55	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-7.2%	449	484	495	522	515	561	617	667	437	437	453	464	480	215
Current Assets	-7.2%	446	480	477	498	399	474	582	623	322	297	329	344	447	212
Cash Equivalents	-24.6%	74.00	98.00	65.00	142	122	156	243	354	76.00	60.00	88.00	124	294	168
Net PPE	-7.7%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-21.5%	24.00	30.00	26.00	22.00	29.00	26.00	31.00	63.00	18.00	12.00	8.00	6.00	10.00	14.00
Current Liabilities	-22.1%	22.00	28.00	23.00	20.00	26.00	22.00	27.00	62.00	17.00	12.00	8.00	6.00	10.00	14.00
Long Term Debt	-100.0%	-	2.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-6.2%	426	454	469	500	486	535	586	605	419	425	445	459	470	200
Retained Earnings	-18.5%	-238	-200	-177	-137	-105	-47.69	-20.91	4.00	-171	-158	-126	-109	-93.41	-93.34
Additional Paid-In Capital	1.4%	664	655	647	639	593	585	611	604	593	585	570	565	560	292
Shares Outstanding	0.4%	43.00	43.00	43.00	43.00	39.00	46.00	46.00	45.00	44.00	44.00	43.00	43.00	-	-
Minority Interest	-100.0%	-	0.00	-	-	-	-	-	0.00	1.00	0.00	2.00	3.00	3.00	1.00
Float	-	-	-	-	374	-	-	-	376	-	-	-	717	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-110.9%	-38,247	-18,131	-34,141	-31,006	-50,997	-24,983	-54,353	-25,420	-21,908	-15,171	-10,551	-16,196	-1,515	-9,436	-9,071	-6,250	-5,015
Share Based Compensation	9.4%	8,227	7,519	7,740	7,920	7,259	-	5,271	8,608	6,565	12,145	4,557	4,165	3,508	-	-	-	-
Cashflow From Investing	-74.8%	12,956	51,470	-42,958	12,110	15,184	-28,610	-57,978	300,852	34,711	-15,862	-25,593	-154,594	-137,726	11,440	-1,941	11,971	-26,890
Cashflow From Financing	337.5%	1,085	248	112	38,602	1,789	-32,912	1,425	2,013	3,541	2,702	579	923	264,580	124,897	1,206	-	14,037
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,359	-	-	213

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CGEM Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 30,646	$ 52,096
General and administrative	12,343	10,660
Total operating expenses	42,989	62,756
Loss from operations	(42,989)	(62,756)
Other income (expense):
Interest income	5,693	4,508
Other income (expense), net	(44)	107
Net loss	(37,340)	(58,141)
Net loss attributable to noncontrolling interests	(192)	(179)
Net loss attributable to common stockholders of Cullinan	(37,148)	(57,962)
Comprehensive income (loss):
Net loss	(37,340)	(58,141)
Unrealized gain (loss) on investments	(202)	1,359
Comprehensive loss	(37,542)	(56,782)
Comprehensive loss attributable to noncontrolling interests	(192)	(179)
Comprehensive loss attributable to Cullinan	$ (37,350)	$ (56,603)
Net loss per share attributable to common stockholders of Cullinan:
Net loss per share, basic	$ (0.86)	$ (1.42)
Net income loss per share, diluted	$ (0.86)	$ (1.42)
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders of Cullinan
Weighted-average common stock outstanding - basic	43,011	40,682
Weighted-average common stock outstanding - diluted	43,011	40,682

CGEM Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 74,228	$ 98,434
Short-term investments	358,783	368,633
Prepaid expenses and other current assets	12,710	13,124
Total current assets	445,721	480,191
Property and equipment, net	913	989
Operating lease right-of-use assets	2,336	2,543
Other assets	460	459
Total assets	449,430	484,182
Current liabilities:
Accounts payable	3,707	2,493
Accrued expenses and other current liabilities	16,889	24,204
Operating lease liabilities, current	1,329	1,440
Total current liabilities	21,925	28,137
Long-term liabilities:
Operating lease liabilities, net of current portion	1,840	2,150
Total liabilities	23,765	30,287
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 647,500 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value, 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 43,065,645 and 42,900,083 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	663,997	654,685
Accumulated other comprehensive loss	(331)	(129)
Accumulated deficit	(238,005)	(200,857)
Total Cullinan stockholders' equity	425,665	453,703
Noncontrolling interests	0	192
Total stockholders' equity	425,665	453,895
Total liabilities and stockholders' equity	$ 449,430	$ 484,182

About Cullinan Management, Inc.

Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Nadim Ahmed
WEBSITE	cullinanoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	62

Cullinan Management, Inc. Frequently Asked Questions

What is the ticker symbol for Cullinan Management, Inc.? What does CGEM stand for in stocks?

CGEM is the stock ticker symbol of Cullinan Management, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cullinan Management, Inc. (CGEM)?

As of Fri May 17 2024, market cap of Cullinan Management, Inc. is 1.33 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGEM stock?

You can check CGEM's fair value in chart for subscribers.

What is the fair value of CGEM stock?

You can check CGEM's fair value in chart for subscribers. The fair value of Cullinan Management, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cullinan Management, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CGEM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cullinan Management, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGEM is over valued or under valued. Whether Cullinan Management, Inc. is cheap or expensive depends on the assumptions which impact Cullinan Management, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGEM.

What is Cullinan Management, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CGEM's PE ratio (Price to Earnings) is -10.09 and Price to Sales (PS) ratio is 14.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGEM PE ratio will change depending on the future growth rate expectations of investors.